Join us on 12-15-2022 for a live seminar about RNA SEQ
Campaigns begin by leveraging our ATX-Gx™ humanized mice platform and its broad diversity of the human antibody sequence space. This increases the number of high-quality, diverse leads against your target of interest.
Based on your specific desired functional characteristics and developability requirements, we’ll deploy one of our advanced, AI/ML-enabled technologies for B-cell repertoire mining and sequencing to interrogate and identify the best hits.
We convert hits to clinical therapeutic candidates by deploying our full-stack expertise and capabilities to engineer your antibody into a range of formats and conduct in vitro and in vivo functional testing in therapeutically relevant models.
This sequence-first approach captures the antibody repertoire then zooms in to screen for desired lead. It focuses on the initial diversity of hits and drives functional discovery by downstream assays and iterative mining of immune repertoire—and is well-suited to therapeutic targets without an initial screening assay, benchmark, or screening reagent(s), particularly in exploratory programs.
This function-forward approach harnesses functional assays to drive functional relevancy of hits from the get-go. It focuses on the early screening of a specific functional attribute, such as specificity and blocking—and is ideal for therapeutic targets with more understood, well-defined biology and readily available functionally relevant assays with the screening reagents already accessible.
We democratize access to foundational, pre-competitive biologics discovery technologies and services.
